UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

In-class transition (iCT) of proteasome inhibitor-based therapy: a community approach to multiple myeloma management

Blood cancer journal (New York), 2023-09, Vol.13 (1), p.147-147, Article 147

2023

Volltextzugriff (PDF)

Recent advances in understanding multiple myeloma [version 1; peer review: 4 approved]

F1000 research, 2016, Vol.5, p.2053

2016

Volltextzugriff (PDF)

A Phase II trial of weekly bortezomib and dexamethasone in veterans with newly diagnosed multiple myeloma not eligible for or who deferred autologous stem cell transplantation

British journal of haematology, 2015-04, Vol.169 (1), p.36-43

2015

Volltextzugriff (PDF)

PB2089: IN‐CLASS TRANSITION FROM PARENTERAL BORTEZOMIB TO ORAL IXAZOMIB IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) ACCORDING TO AGE AND FRAILTY STATUS: UPDATED SUBGROUP ANALYSIS OF US MM‐6

HemaSphere, 2023-08, Vol.7 (S3), p.e149880d-n/a

2023

Volltextzugriff (PDF)

Triplet versus doublet therapy in multiple myeloma patients over 75 years

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e20519-e20519

2020

Volltextzugriff (PDF)

Hepatic response after high-dose melphalan and stem cell transplantation in patients with AL amyloidosis associated liver disease

Haematologica (Roma), 2009-07, Vol.94 (7), p.1029-1032

2009

Volltextzugriff (PDF)

Practice Patterns in Newly Diagnosed Multiple Myeloma in the Prospective Observational Commpass Trial

Blood, 2016-12, Vol.128 (22), p.4502-4502

2016

Volltextzugriff (PDF)

In-Class Transition ( iCT) from Parenteral Bortezomib (V) to Oral Ixazomib Therapy in Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) in the Community-Based US MM-6 Study: Subanalysis of Randomized Controlled Trial (RCT)-Ineligible and RCT-Eligible Pts

Blood, 2023-11, Vol.142 (Supplement 1), p.6677-6677

2023

Volltextzugriff (PDF)

Genomic Landscape of Sex Disparities in Multiple Myeloma

Blood, 2019-11, Vol.134 (Supplement_1), p.3067-3067

2019

Volltextzugriff (PDF)

Genomic Landscape of Multiple Myeloma with Elevated Lactate Dehydrogenase

Blood, 2018-11, Vol.132 (Supplement 1), p.470-470

2018

Volltextzugriff (PDF)

Clinical Outcomes of Newly Diagnosed Multiple Myeloma Patients with Elevated Lactate Dehydrogenase Who Underwent Autologous Hematopoietic Stem Cell Transplantation

Blood, 2018-11, Vol.132 (Supplement 1), p.4623-4623

2018

Volltextzugriff (PDF)

In-Class Transition (iCT) from Parenteral Bortezomib to Oral Ixazomib Therapy in Newly Diagnosed Multiple Myeloma (NDMM) Patients from the Community-Based US MM-6 Study: Subgroup Analyses of the Fully Accrued Dataset in Patients Aged <75 and ≥75 Years

Blood, 2022-11, Vol.140 (Supplement 1), p.7322-7323

2022

Volltextzugriff (PDF)

Male breast cancer: a gender issue

Nature clinical practice. Oncology, 2006-08, Vol.3 (8), p.428-437

2006

Volltextzugriff (PDF)

Overview of systemic and localized amyloidosis

Reviews in health care, 2013-10, Vol.4 (4), p.231-247

Girnius, Saulius

2013

Volltextzugriff (PDF)

Bleeding and thrombotic risk in pregnant women with Fontan physiology

Heart (British Cardiac Society), 2021-09, Vol.107 (17), p.1390-1397

2021

Volltextzugriff (PDF)

Recombinant Porcine Factor VIII, Obi-1, Successfully Controlled Gastrointestinal Bleeding in a Patient with Acquired Hemophilia A

Blood, 2015-12, Vol.126 (23), p.4676-4676

2015

Volltextzugriff (PDF)

Extended Characterization of Newly Diagnosed Multiple Myeloma (NDMM) Patients with In-Class Transition (iCT) from Parenteral Bortezomib to Oral Ixazomib Proteasome Inhibitor (PI) Therapy in the Community-Based United States (US) MM-6 Study: Updated Efficacy and Safety, and Reasons for Premature Discontinuation

Blood, 2021-11, Vol.138 (Supplement 1), p.2726-2726

2021

Volltextzugriff (PDF)

P-114 In-class transition (iCT) from parenteral bortezomib (V) to oral ixazomib in multiple myeloma (MM) by age and frailty status: updated subgroup analysis from the fully accrued US MM-6 study

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S97-S98

2023

Volltextzugriff (PDF)

Autologous hematopoietic cell transplantation for multiple myeloma patients with renal insufficiency: a center for international blood and marrow transplant research analysis

Bone marrow transplantation (Basingstoke), 2017-12, Vol.52 (12), p.1616-1622

2017

Volltextzugriff (PDF)

Primary Plasma Cell Leukemia Outcomes Remain Dismal Despite Novel Agents and Hematopoietic Cell Transplantation

Blood, 2019-11, Vol.134 (Supplement_1), p.266-266

2019

Volltextzugriff (PDF)

In-Class Transition (iCT) from Parenteral Bortezomib to Oral Ixazomib Proteasome Inhibitor (PI) Therapy Increases the Feasibility of Long-Term PI Treatment and Benefit for Newly Diagnosed Multiple Myeloma (NDMM) Patients in an Outpatient Setting: Updated Real-World Results from the Community-Based United States (US) MM-6 Study

Blood, 2020-11, Vol.136 (Supplement 1), p.2-4

2020

Volltextzugriff (PDF)

Individualized Therapy in Multiple Myeloma: Are We There?

Seminars in oncology, 2013-10, Vol.40 (5), p.567-576

2013

Volltextzugriff (PDF)

A rare case of central nervous system amyloidoma treated with fractionated radiotherapy

Journal of neurosurgery, 2017-08, Vol.127 (2), p.338-341

2017

Volltextzugriff (PDF)

Phase 1b/2 Study of the First-in-Class SUMO-Activating Enzyme Inhibitor TAK-981 in Combination with Monoclonal Antibodies in Patients with Triple-Class Refractory Multiple Myeloma

Blood, 2021-11, Vol.138 (Supplement 1), p.2742-2742

2021

Volltextzugriff (PDF)

1 – 25 von 80

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(62)
Mit Volltextzugriff
(63)

Publikationsform

Sprache

Englisch
(80)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: A CIBMTR report

In-class transition (iCT) of proteasome inhibitor-based therapy: a community approach to multiple myeloma management

Recent advances in understanding multiple myeloma [version 1; peer review: 4 approved]

A Phase II trial of weekly bortezomib and dexamethasone in veterans with newly diagnosed multiple myeloma not eligible for or who deferred autologous stem cell transplantation

PB2089: IN‐CLASS TRANSITION FROM PARENTERAL BORTEZOMIB TO ORAL IXAZOMIB IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) ACCORDING TO AGE AND FRAILTY STATUS: UPDATED SUBGROUP ANALYSIS OF US MM‐6

Triplet versus doublet therapy in multiple myeloma patients over 75 years

Hepatic response after high-dose melphalan and stem cell transplantation in patients with AL amyloidosis associated liver disease

Practice Patterns in Newly Diagnosed Multiple Myeloma in the Prospective Observational Commpass Trial

In-Class Transition ( iCT) from Parenteral Bortezomib (V) to Oral Ixazomib Therapy in Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) in the Community-Based US MM-6 Study: Subanalysis of Randomized Controlled Trial (RCT)-Ineligible and RCT-Eligible Pts

Genomic Landscape of Sex Disparities in Multiple Myeloma

Genomic Landscape of Multiple Myeloma with Elevated Lactate Dehydrogenase

Clinical Outcomes of Newly Diagnosed Multiple Myeloma Patients with Elevated Lactate Dehydrogenase Who Underwent Autologous Hematopoietic Stem Cell Transplantation

In-Class Transition (iCT) from Parenteral Bortezomib to Oral Ixazomib Therapy in Newly Diagnosed Multiple Myeloma (NDMM) Patients from the Community-Based US MM-6 Study: Subgroup Analyses of the Fully Accrued Dataset in Patients Aged <75 and ≥75 Years

Male breast cancer: a gender issue

Overview of systemic and localized amyloidosis

Bleeding and thrombotic risk in pregnant women with Fontan physiology

Recombinant Porcine Factor VIII, Obi-1, Successfully Controlled Gastrointestinal Bleeding in a Patient with Acquired Hemophilia A

P-114 In-class transition (iCT) from parenteral bortezomib (V) to oral ixazomib in multiple myeloma (MM) by age and frailty status: updated subgroup analysis from the fully accrued US MM-6 study

Autologous hematopoietic cell transplantation for multiple myeloma patients with renal insufficiency: a center for international blood and marrow transplant research analysis

Primary Plasma Cell Leukemia Outcomes Remain Dismal Despite Novel Agents and Hematopoietic Cell Transplantation

Individualized Therapy in Multiple Myeloma: Are We There?

A rare case of central nervous system amyloidoma treated with fractionated radiotherapy

Phase 1b/2 Study of the First-in-Class SUMO-Activating Enzyme Inhibitor TAK-981 in Combination with Monoclonal Antibodies in Patients with Triple-Class Refractory Multiple Myeloma

Suchergebnisse filtern